| 摘要 |
A method for prediction of risk of development of acute myeloblast leukemia prescribes blood investigation. In blood serum one determines the level of thymidine kinase and &bgr;-microblobulin before beginning of treatment and after the end of reduction of emission, and at level of thymidine kinase from 10.1 to 20.0 U/l average risk is predicted, the level more than 20.0 U/l points out prevalence rate and severe prognosis. Most unfavorable prognosis is observed at the level of thymidine kinase more than 30.0 U/l, increase of the level of thymidine kinase in period of remission >5.0 U/l indicates on not complete clinical-hematological response on treatment carried out, with prediction of development of recurrence of disease irrespectively of clinical-hematological characteristics. |
